PIK3CA and neoplasm: Consistent with these observations, we and others have demonstrated enhanced anti-tumour efficacy in preclinical models of HER2-amplified breast cancer by combining PI3K pathway inhibitors with trastuzumab or lapatinib (7,16,23–26).